{"name":"Candel Therapeutics","slug":"candel","ticker":"CADL","exchange":"NASDAQ","domain":"candeltherapeutics.com","description":"Candel Therapeutics (CADL) is a biotechnology company focused on developing viral immunotherapies for the treatment of cancer. The company's pipeline includes several promising candidates, including its lead product, CNDT-001. With a strong focus on oncology, Candel Therapeutics is well-positioned to capitalize on the growing demand for innovative cancer treatments.","hq":"Needham, MA","founded":0,"employees":"","ceo":"Paul Peter Tak","sector":"Oncology / Viral Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$320M","metrics":{"revenue":125000,"revenueGrowth":0,"grossMargin":0,"rdSpend":30496000,"netIncome":-38182000,"cash":125195000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"CNDT-001 patent cliff ($0.00 at risk)","drug":"CNDT-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","indication":"Metastatic pancreatic cancer","status":"phase_3"},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","indication":"Metastatic solid tumors","status":"phase_2"},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","indication":"Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)","status":"phase_3"},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","indication":"Metastatic pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","phase":"phase_3","mechanism":"AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","phase":"phase_2","mechanism":"CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","phase":"phase_3","mechanism":"Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.","indications":["Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)"],"catalyst":""},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","phase":"phase_3","mechanism":"Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Candel Therapeutics Announces FDA Clearance of IND for CNDT-001","summary":"Candel Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for CNDT-001, enabling the company to initiate a Phase 1 clinical trial.","drugName":"CNDT-001","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Candel Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Candel Therapeutics reported its third-quarter 2023 financial results, highlighting progress in its clinical pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Candel Therapeutics Enters into Collaboration Agreement with Leading Cancer Research Institution","summary":"Candel Therapeutics announced a collaboration agreement with a leading cancer research institution to advance the development of its viral immunotherapies.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxORHRrTWpnVldxOC10bmxfZ05TdzJ4Z1JIMXJWTXppd3FkeXdjclFmd0thZEphVzdjRmxQYkxVbHN6VWJ2dE92UWxsOUhibGw5UndIb3BRVGhsdlpZb1h5elVsam1PYk9wNWM0RExyNTRfYlNmdDBkVG9pQllmRG1qSC1MVlBObF9qai1wVEFWWGtvWUdoWkx1QURic1A2Snc2QkhiMEhyQ0R6VXY1QVBFZ1NYTQ?oc=5","date":"2026-02-23","type":"pipeline","source":"The Pharma Letter","summary":"Candel Therapeutics announces pricing of $100 million public offering - The Pharma Letter","headline":"Candel Therapeutics announces pricing of $100 million public offering","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQS2VKS21XU2tnTkRPRFNiQ3R0aE1kR1U4RllzZE5uOVFwWW1yY2xEaHB6UUkzMUdGQmlQRVk4dVlWeTN0ZnFnak5hd2hPc3liTUNhak5XTWFqN1NNUjFwTm1FYU9OS3Z3TGFyQzV1bTFqZGVOUlhyU2QyM3VaNkhhRmN1T2ZiNjNXNWNPZmdvNzZhTFE3M1hpUi1MWlMtMVJ6NGdZNUJralFqOFg4d1hlanBpTTM?oc=5","date":"2026-02-20","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQYWZpQkZBbG41XzY1YXZ3UmdMMVYwdXd0SHFJSkJaV0pHNGhrMnV4YVhFY2VjQkVoZTU0b1p6QzZTcFlFOVlfYXBRQWJGcldyRWZfa3V0TzdNS2g5VlViNzJsdTZ0YlZhc3pxd2NtVkFfaGZaSDZuTHo0SzhTSmhDdDNXcnViaVB5dXBCbFZkelcxZXo5U1BoN3pLRGZDZEhNLWhKeEc4YXdnblQ5MnlhVjJQTHdxZjBrbGc?oc=5","date":"2026-02-20","type":"pipeline","source":"proactiveinvestors.com","summary":"Candel Therapeutics prices $100M public offering - proactiveinvestors.com","headline":"Candel Therapeutics prices $100M public offering","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNS05IbnFMNEVHSTdxNkd5aXk1OU5aNU1uM2FDQ0daY29EcGdPdUlDZGhPLTFrNmxIRzl6RF9IcGc0TElQMFg0ZE9XN05GQTNCVjd3NjdTeHRmd2lPelBhdnNnQ1JZdjEyWlNCTzBfQUNMNEJWN1ZwRzFWaWVhejNXRVBZWWZfMThZbzlPU3V2ZTFaVFFPQm40bHJ4TktzUmR4ajRjWmt4TktEWVRVdGlFNlF4Y2hiWGVaaTVuakJSbnp0Ry1jN3A2UTRBWDdENGtueGFUSmpxUUg1Z0pkSGJaUmJNUmJBZXM?oc=5","date":"2026-02-11","type":"trial","source":"proactiveinvestors.com","summary":"Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL - proactiveinvestors.com","headline":"Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"pipeline","source":"simplywall.st","summary":"Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st","headline":"Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQX1pEOTJvZzZKa1g5X0kxendaN2lNVHpBZzFmSGpuOWZKS01BVUlrYVViWVV5cGRJZHNUc29hNnFqQWg4REptbno1X054ZlQxUjFZaWZ6X2ROdnJ0TUNsUTNfLXBWV0NWeDZnSXlqNDBLTzFuQjA1MVVvXzNiMTVoWWNJQTVRb3NISF9BUHlDS1dzN3JhTmVITVFUcEhIVUtPaUtjMU1jUHZkTU8wUXpUZTF2c0c5MkdoNWdXMTEwZXBKQXZXRTViZ2dHaDZYbFlTbktOcUlTOFU3QlJvOWh1QVhUT29uZXlreWNOZlZmbXNsOXBlVFdNWFhJY2R6VWoxeEtN?oc=5","date":"2025-12-11","type":"pipeline","source":"Benzinga","summary":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On - Benzinga","headline":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQam5ZdzFUTXk5OGMzN2lJZ19mT19Eb0RGNWM3cEp1MWtTLS1sNWZMb0xYbDJfUE5ibzE4SERpYUZvd1MySUdnWWRtQjl6bURYSGM5LTlfdjIyWmJlNHVyMGZWOXVmZE5sVlJRVmFmQzBCdUxjaXBzOWhLWGk2TnVzanoyaEhSeVpHX2VwZ3IxQmpxRmtBVWdoLTd2bi1tcS1qYnhPMmdkSUpTYTBBMFVJaQ?oc=5","date":"2025-10-13","type":"regulatory","source":"Seeking Alpha","summary":"Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha","headline":"Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-15","type":"pipeline","source":"simplywall.st","summary":"Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st","headline":"Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUUVwYUNIMHQ5SjljcmFwV0dOYmM4TUJXRHNUajQ3SVA1Q0hZVjF1M0lJSlE5d0hNaFdoNHlDSUhKZFF1cmxkaGFaMlNQdXdjeEY2eHAtTTluU3h4RDZOTUw3UUd0ajQ2YzFiOU85VGRVcWFTTHNFcmowWjZmMmtQVnBlbkpTekNEMDExMzg1RnExNU9IVjZybjNzMkRFZVp1YzM2YUxHT2tScUNjVEVnSGxSTHpQZXJLUjEyUTVkQ2loQUVfYUVoellzMWdVQi1pUU5Ka1AtSzAzOXJCZFRVSEJKTzhoZ09yMzJ6U2tYSTh6REp5WHpRNFRpMmt6QQ?oc=5","date":"2025-05-27","type":"trial","source":"Proactive financial news","summary":"Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news","headline":"Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy","sentiment":"positive"}],"patents":[{"drugName":"CNDT-001","drugSlug":"cndt-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":4,"phaseCounts":{"phase_3":3,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Oncology","Viral Immunotherapy"],"financials":{"source":"sec_edgar+yahoo","revenue":125000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":125000,"period":"2022-12-31"},{"value":125000,"period":"2022-12-31"},{"value":125000,"period":"2021-12-31"},{"value":125000,"period":"2021-12-31"},{"value":125000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":30496000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-38182000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":125195000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}